Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

## VOLUNTARY ANNOUNCEMENT SELECTION RESULTS OF NATIONAL CENTRALISED MEDICINES PROCUREMENT

The board of directors (the "Board") of SSY Group Limited (the "Company", together with its subsidiaries, the "Group") is pleased to announce that, a total of 12 products with 14 specifications of the Group were selected in the respective tender results of the eleventh batch of the National Centralised Medicines Procurement (全國藥品集中採購) in China on 27 October 2025 as follows: Diprophylline Injection (2ml:0.3g), Formoterol Fumarate Inhalation Solution (2ml:20µg), Fluvoxamine Maleate Tablets (100mg and 50mg), Lornoxicam for Injection (8mg), Epinephrine Hydrochloride Injection (1ml:1mg), Bromhexine Hydrochloride Injection (2ml:4mg), Multiple Electrolyte Injection (500ml), Multiple Electrolyte Injection (II) (500ml and 1000ml), Nicorandil Tablets (5mg), Salbutamol Sulfate Injection (1ml:0.5mg), Benidipine Hydrochloride Tablets (8mg) and Sodium Bicarbonate Injection (50ml:4.2g)

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board
Chow Hing Yeung
Executive Director and Company Secretary

Hong Kong, 28 October 2025

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo, Mr. Chow Hing Yeung and Ms. Qu Wanrong as executive Directors, Mr. Liu Wenjun as non-executive Director, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.